Page 4 - Dr Reddy's

Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vax

Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. "The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its ...

Dr Reddy's to get 36 mn doses of Sputnik V vaccine in next few months

The drugmaker on Friday reported a 27.6% drop in fourth-quarter consolidated net profit, compared with a year earlier.

Dr Reddy's receives DCGI approval for restricted emergency use of Sputnik V

Drug major Dr Reddy's Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of Covid-19 vaccine Sputnik V in the country

India approves Sputnik V vaccine, to produce 850 mn doses annually: RDIF

The RDIF has said that India has become the 60th country to approve the use of Sputnik V against coronavirus

Dr Reddy's to submit more data on Covid-19 vaccine Sputnik V by July

Colour-coded doses will have two different antigens

Dr Reddy s eyes to launch Sputnik V vaccine for Covid-19 under EUA in March

Dr Reddys Laboratories (DRL) on Friday said it expected Russia's COVID-19 vaccine Sputnik V to be launched in India through Emergency Use Authorisation (EUA) by March this year.

Dr Reddy's seeks nod from Canada for Favipiravir pills for Covid treatment

Dr Reddy's Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 adult patients

DRL, RDIF commence clinical trials for Sputnik V Covid-19 vaccine in India

Dr Reddy's Laboratories and Russian Direct Investment Fund (RDIF) on Tuesday said they have commenced adaptive phase 2/3 clinical trials for the Sputnik V COVID-19 vaccine in India. The trials have commenced after receiving the necessary clearance from the Kasauli-based Central Drugs Laboratory, they added. This will be a multicentre and randomised controlled study, which will include safety and immunogenicity study, the Hyderabad-based drug maker and RDIF said in a joint statement. The clinical trials are being conducted by JSS Medical Research as the clinical research partner. Further, Dr Reddy's has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC's clinical trial centres for the vaccine, it added. Recently, RDIF had announced the second interim analysis of clinical trial data, which showed 91.4 per cent efficacy for the vaccine on day 28 after the first dose; and efficacy of o

Analysts slash FY22 profit estimates; telecom, PSU banking firms suffer

An analysis done by Motilal Oswal Financial Services (MOFSL) shows, health care and technology are the only two sectors which have seen an upgrade in FY22 earnings

Healthy growth in India, US helps Dr Reddy's post strong Q2 performance

Wockhardt buy, Covid portfolio aid India business growth

Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Dr Reddy's Laboratories shuts all units after cyber attack on servers

Security breach comes days after firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V

Dr Reddy's gets nod for 2/3 vaccine trial; Key updates about the virus

A PMO release said three vaccines are in advanced stages of development in India, out of which two are in Phase II and one is in Phase-III

India trials for Russia's Covid vaccine may start in few weeks: Dr Reddy's

The trials are part of a deal between the Russian Direct Investment Fund and Dr Reddy's.

Russian vaccine on its way to India, pact signed with Dr Reddy's for trials

Talks are also on with five major Indian manufacturers here to produce the vaccine for India and the world

Russia to supply 100 million doses of Sputnik V vaccine to Dr Reddy's

The Russian Direct Investment Fund said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine in India

Dr Reddy's Laboratories launches drug to treat infections in US market

Ciprodexis used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria

Dr Reddy's: Strong Q1 show in spite of disruption lifts sentiment

Normalising US and India sales likely to drive earnings in FY21

Dr Reddy's Q1 PAT falls 13% to Rs 579 cr, revenue up by 15% to Rs 4,417 cr

Commenting on the results, co-chairman and MD, G V Prasad said "the current quarter's financial performance has been strong across all parameters

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter